358 related articles for article (PubMed ID: 33407700)
1. Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Xuan L; Liu Q
J Hematol Oncol; 2021 Jan; 14(1):4. PubMed ID: 33407700
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update.
Battipaglia G; Massoud R; Ahmed SO; Legrand O; El Cheikh J; Youniss R; Aljurf M; Mohty M; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):506-508. PubMed ID: 31122828
[TBL] [Abstract][Full Text] [Related]
3. Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.
Xuan L; Wang Y; Huang F; Jiang E; Deng L; Wu B; Fan Z; Liang X; Xu N; Ye J; Lin R; Yin C; Zhang Y; Sun J; Han M; Huang X; Liu Q
Cancer; 2018 May; 124(9):1954-1963. PubMed ID: 29509276
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD-Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation.
Schiller GJ; Tuttle P; Desai P
Biol Blood Marrow Transplant; 2016 Jun; 22(6):982-990. PubMed ID: 26785334
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With
Burchert A; Bug G; Fritz LV; Finke J; Stelljes M; Röllig C; Wollmer E; Wäsch R; Bornhäuser M; Berg T; Lang F; Ehninger G; Serve H; Zeiser R; Wagner EM; Kröger N; Wolschke C; Schleuning M; Götze KS; Schmid C; Crysandt M; Eßeling E; Wolf D; Wang Y; Böhm A; Thiede C; Haferlach T; Michel C; Bethge W; Wündisch T; Brandts C; Harnisch S; Wittenberg M; Hoeffkes HG; Rospleszcz S; Burchardt A; Neubauer A; Brugger M; Strauch K; Schade-Brittinger C; Metzelder SK
J Clin Oncol; 2020 Sep; 38(26):2993-3002. PubMed ID: 32673171
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
Lee CJ; Shiraz P; Muffly L
Leuk Lymphoma; 2017 Mar; 58(3):516-527. PubMed ID: 27685315
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.
Antar A; Kharfan-Dabaja MA; Mahfouz R; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):298-302. PubMed ID: 25550214
[TBL] [Abstract][Full Text] [Related]
8. High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
De Freitas T; Marktel S; Piemontese S; Carrabba MG; Tresoldi C; Messina C; Lupo Stanghellini MT; Assanelli A; Corti C; Bernardi M; Peccatori J; Vago L; Ciceri F
Eur J Haematol; 2016 Jun; 96(6):629-36. PubMed ID: 26260140
[TBL] [Abstract][Full Text] [Related]
9. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis.
Bewersdorf JP; Allen C; Mirza AS; Grimshaw AA; Giri S; Podoltsev NA; Gowda L; Cho C; Tallman MS; Zeidan AM; Stahl M
Transplant Cell Ther; 2021 Dec; 27(12):997.e1-997.e11. PubMed ID: 34551341
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
Battipaglia G; Ruggeri A; Massoud R; El Cheikh J; Jestin M; Antar A; Ahmed SO; Rasheed W; Shaheen M; Belhocine R; Brissot E; Dulery R; Eder S; Giannotti F; Isnard F; Lapusan S; Rubio MT; Vekhoff A; Aljurf M; Legrand O; Mohty M; Bazarbachi A
Cancer; 2017 Aug; 123(15):2867-2874. PubMed ID: 28387928
[TBL] [Abstract][Full Text] [Related]
11. [Hematopoietic cell transplantation for FLT3-mutated acute myeloid leukemia].
Hosono N
Rinsho Ketsueki; 2022; 63(9):1242-1251. PubMed ID: 36198550
[TBL] [Abstract][Full Text] [Related]
12. FLT3 inhibitors as maintenance therapy post allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with FLT3 mutations: A meta-analysis.
Fei X; Zhang S; Gu J; Wang J
Cancer Med; 2023 Mar; 12(6):6877-6888. PubMed ID: 36411731
[TBL] [Abstract][Full Text] [Related]
13. FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation.
Biavasco F; Zeiser R
Int J Hematol; 2022 Sep; 116(3):341-350. PubMed ID: 35460465
[TBL] [Abstract][Full Text] [Related]
14. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.
Brunner AM; Li S; Fathi AT; Wadleigh M; Ho VT; Collier K; Connolly C; Ballen KK; Cutler CS; Dey BR; El-Jawahri A; Nikiforow S; McAfee SL; Koreth J; Deangelo DJ; Alyea EP; Antin JH; Spitzer TR; Stone RM; Soiffer RJ; Chen YB
Br J Haematol; 2016 Nov; 175(3):496-504. PubMed ID: 27434660
[TBL] [Abstract][Full Text] [Related]
15. [Sorafenib combined with chemotherapy and donor lymphocyte infusion as salvage therapy in patients with FLT3-positive acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation].
Xuan L; Fan ZP; Zhang Y; Xu N; Ye JY; Zhou X; Wang ZX; Sun J; Liu QF; Huang F
Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):351-354. PubMed ID: 29747291
[TBL] [Abstract][Full Text] [Related]
16. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
17. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
Sharma M; Ravandi F; Bayraktar UD; Chiattone A; Bashir Q; Giralt S; Chen J; Qazilbash M; Kebriaei P; Konopleva M; Andreeff M; Cortes J; McCue D; Kantarjian H; Champlin RE; de Lima M
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1874-7. PubMed ID: 21767516
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial.
Ganguly S; Cortes JE; Krämer A; Levis MJ; Martinelli G; Perl AE; Russell NH; Arunachalam M; Santos CD; Gammon G; Lesegretain A; Mires DE; Pham H; Wang Y; Khaled SK
Transplant Cell Ther; 2021 Feb; 27(2):153-162. PubMed ID: 33017662
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update.
Hu B; Vikas P; Mohty M; Savani BN
Expert Rev Hematol; 2014 Apr; 7(2):301-15. PubMed ID: 24308526
[TBL] [Abstract][Full Text] [Related]
20. Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.
Nasilowska-Adamska B; Czyz A; Markiewicz M; Rzepecki P; Piatkowska-Jakubas B; Paluszewska M; Dzierzak-Mietla M; Solarska I; Borg K; Prochorec-Sobieszek M; Szydlo R; Lewandowski K; Skotnicki A; Jedrzejczak WW; Kyrcz-Krzemien S; Komarnicki M; Warzocha K
Eur J Haematol; 2016 Mar; 96(3):236-44. PubMed ID: 25912052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
